Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 210542
Company: ZYDUS PHARMS USA INC
Company: ZYDUS PHARMS USA INC
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE | 50MG;500MG | TABLET;ORAL | None (Tentative Approval) | None | No | No |
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE | 50MG;1000MG | TABLET;ORAL | None (Tentative Approval) | None | No | No |
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE | 150MG;500MG | TABLET;ORAL | None (Tentative Approval) | None | No | No |
CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE | CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE | 150MG;1000MG | TABLET;ORAL | None (Tentative Approval) | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
02/16/2023 | ORIG-1 | Tentative Approval | STANDARD |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/210542Orig1s000TAltr.pdf |